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PURPOSE. To employ type II clustered regularly interspaced short palindromic repeats
(CRISPR)-Cas9 endonuclease to suppress ocular angiogenesis by genomic disruption of VEGF-
A in human RPE cells.
METHODS. CRISPR sequences targeting exon 1 of human VEGF-A were computationally
identified based on predicted Cas9 on- and off-target probabilities. Single guide RNA (gRNA)
cassettes with these target sequences were cloned into lentiviral vectors encoding the
Streptococcus pyogenes Cas9 endonuclease (SpCas9) gene. The lentiviral vectors were used to
infect ARPE-19 cells, a human RPE cell line. Frequency of insertion or deletion (indel)
mutations was assessed by T7 endonuclease 1 mismatch detection assay; mRNA levels were
assessed with quantitative real-time PCR; and VEGF-A protein levels were determined by
ELISA. In vitro angiogenesis was measured using an endothelial cell tube formation assay.
RESULTS. Five gRNAs targeting VEGF-A were selected based on the highest predicted on-target
probabilities, lowest off-target probabilities, or combined average of both scores. Lentiviral
delivery of the top-scoring gRNAs with SpCas9 resulted in indel formation in the VEGF-A gene
at frequencies up to 37.0% 6 4.0% with corresponding decreases in secreted VEGF-A protein
up to 41.2% 6 7.4% (P < 0.001), and reduction of endothelial tube formation up to 39.4% 6
9.8% (P ¼ 0.02). No significant indel formation in the top three putative off-target sites tested
was detected.
CONCLUSIONS. The CRISPR-Cas9 endonuclease system may reduce VEGF-A secretion from
human RPE cells and suppress angiogenesis, supporting the possibility of employing gene
editing for antiangiogenesis therapy in ocular diseases.
Keywords: CRISPR-Cas9, gene editing, VEGF-A
In recent years, the advent of antiangiogenesis agentstargeting VEGF has revolutionized the treatment of neovas-
cular and exudative retinal diseases ranging from choroidal
neovascularization in AMD to macular edema associated with
diabetes mellitus and retinal vein occlusions. Current anti-VEGF
therapies in clinical practice include humanized antibodies
(bevacizumab); antibody fragments (ranibizumab); and recom-
binant decoy receptor proteins (aflibercept) that are directed
against various secreted isoforms of VEGF-A.1–3 However,
frequent intravitreal injections of these drugs are a heavy
burden to clinicians and patients, and pose significant costs to
health care.
Viral-mediated gene therapy holds the promise for providing
a longer duration of VEGF inhibition. Adeno-associated viral
(AAV) expression of sFlt-1, a soluble form of the VEGF receptor,
reduces laser-induced choroidal neovascularization in monkeys
and is undergoing clinical trials for patients with neovascular
AMD.4–6 Gene silencing with small-interfering RNAs or micro-
RNAs against VEGF has also demonstrated success in reducing
ocular neovascularization.7–9 However, these RNA-targeted
strategies are susceptible to off-target effects, and the efficiency
of gene knockdown is difficult to predict.10 Moreover, the
duration of viral-mediated gene therapy remains uncertain.
Long-term follow-up of Leber congenital amaurosis type 2
patients who received the RPE65 gene via AAV-mediated
transduction showed possible loss of efficacy after 2 to 3
years.11,12
Rather than targeting angiogenic factors at the protein or
RNA level, gene editing technology using the type II clustered
regularly interspaced short palindromic repeats (CRISPR)-Cas9
endonuclease system enables permanent disruption of the
encoding genes at the DNA level. Derived from the adaptive
immune system of bacteria, the CRISPR-associated Cas9
endonuclease has the ability to introduce double-strand breaks
(DSB) at a specific locus in genomic DNA by recognition of a
specific 20-nucleotide DNA sequence and a 50-NGG-30 proto-
spacer adjacent motif by a CRISPR RNA sequence (crRNA)
combined with a trans-activating crRNA (tracrRNA). By
engineering a single guide RNA (gRNA) to mimic this two-
RNA structure, the Cas9 endonuclease can be programmed to
create precise DSBs that trigger error-prone nonhomologous
end-joining repair pathways, resulting in insertions/deletions
(indels) which can cause nonsense or frameshift mutations to
permanently disrupt the target gene at the genomic level. In
vivo ablation of a dominant rhodopsin mutation using CRISPR-
Cas9 has shown anatomic and functional improvements in a rat
iovs.arvojournals.org j ISSN: 1552-5783 5490
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model of retinitis pigmentosa.13 Gene editing has also been
used to repair a point mutation associated with X-linked
retinitis pigmentosa in patient-derived induced pluripotent
stem cells.14 However, the potential use of CRISPR technology
to target angiogenic factors has not yet been explored.
In this study, we employed a CRISPR-Cas9 genome editing
strategy to disrupt the VEGF-A gene in human RPE cells. We
designed a set of five gRNAs to target exon 1 of VEGF-A based
on computational predictions of on-target and off-target
probabilities; then cloned these gRNAs into lentiviral vectors
encoding the Streptococcus pyogenes Cas9 (SpCas9) endonu-
clease. We found that lentiviral delivery of select gRNAs with
SpCas9 resulted in up to 37.0% 6 4.0% indel formation, with a
corresponding reduction in secreted VEGF-A protein, suppres-
sion of angiogenesis in vitro, and no detectable off-target
effects. These studies provide as proof of concept the
possibility of employing genome engineering techniques for
potential antiangiogenesis therapy in ocular diseases.
METHODS
gRNA and Lentiviral Vector Design
CRISPR gRNAs were computationally designed to predict Cas9
activity, using gRNA design software (Benchling, San Francisco,
CA, USA) to determine an on-target score that predicts Cas9
cleavage efficiency using algorithms previously described,15,16
and CRISPR design software from Feng Zhang Lab (MIT,
Cambridge, CA, USA) to calculate an off-target score that
denotes an inverse probability of Cas9 off-target binding.17
Both scores are presented on a scale from 1 to 100, with a
higher on-target score predicting higher Cas9 activity and a
higher off-target score predicting lower off-target binding. Two
gRNAs were designed using commercial CRISPR design
services from GeneArt (Thermo Fisher Scientific, Waltham,
MA, USA). Target sequences were cloned into the lentiCRISPR
v2 plasmid (Addgene plasmid# 52961) via BsmBI restriction
enzyme sites upstream of the scaffold sequence of the U6-
driven gRNA cassette. The single-vector lentiviral system also
includes SpCas9 expressed from an elongation factor 1a short
promoter with a FLAG octapeptide tag and a puromycin
resistance selection marker linked by a 2A self-cleaving
peptide.18 Lentiviral vectors were produced using the triple
transfection method with calcium phosphate as previously
described,19 and were packaged by the Univeristy of California,
(UC) Davis Center for Vision Science Molecular Construct and
Packaging core facility (Davis, CA, USA).
Cell Culture and Lentiviral Transduction
Human RPE cell line ARPE-19 cells were cultured in Dulbecco’s
modified Eagle’s medium:F12 (DMEM:F12, ATCC, Manassas,
VA, USA) supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Norcross, GA, USA), 0.45% glucose, and penicillin/
streptomycin 100 units/mL; 100 lg/mL (Life Technologies,
Benicia, CA, USA), in a humidified incubator with 5% CO2 at
378C. Cells were grown to 70% confluence and infected with
lentiviral vectors at a multiplicity of infection (MOI) of 2 to 3.
The media was changed 1 day after viral transduction and
incubated for 3 days before selection with 1.5 lg/mL
puromycin (EMD Millipore, Hayward, CA, USA) for 4 days.
Genomic DNA, total mRNA, and conditioned media were
collected at 14 days after viral transduction.
T7 Endonuclease I Assay
Genomic DNA from infected cells were extracted with a
commercial kit (DNeasy Blood and Tissue Kit; Qiagen, Hilden,
Germany) following manufacturer’s protocol, and quantified
using a spectrophotometer (NanoDrop 2000c; Thermo Fisher
Scientific). The targeted regions in exon 1 of the VEGF-A gene
were PCR-amplifed with high-fidelity DNA polymerase (Phu-
sion; New England Biolabs, Ipswich, MA, USA) using primers
flanking the target sites (Supplemental Table S1) and purified
with a PCR purification kit (QIAquick; Qiagen). We denatured
200 ng of the PCR product then slowly hybridized to form
heteroduplexes using the following program settings: 958C for
5 minutes, 958 to 858C at28C/second, 858 to 258C at0.18C/
second. Heteroduplexes were digested with T7 endonuclease I
(New England Biolabs) at 378C for 15 minutes. The reaction
was stopped with 0.02 M EDTA, and the digested products
were separated on a 2% TBE agarose gel for analysis. Band
intensites were measured using ImageJ (http://imagej.nih.gov/
ij/; provided in the public domain by the National Institutes of
Health, Bethesda, MD, USA) and the percentage of indel
formation was calculated using the equation: indel%¼1003 (1
– [1 – fcut]
1/2), where fcut (cut fraction) is the total relative
density of the cleavage bands divided by the sum of the relative
density of the cleavage and uncut bands, as previously
described.20
DNA Sequencing
Sanger sequencing of PCR products amplified from genomic
DNA, using sequencing primers approximately 200 to 250 bp
upstream from predicted cut sites (Supplemental Table S1),
were performed by the UC Davis DNA sequencing facility.
Deep sequencing of PCR products using primers flanking the
target sites (Supplemental Table S1) was performed by the
Massachusetts General Hospital DNA sequencing core facility
(Cambridge, MA, USA).
Quantitative RT-PCR analysis
Virally transduced ARPE-19 cells were collected and stored
(RNAlater; Thermo Fisher Scientific). Total RNA was then
extracted and purified using an RNA purification kit (RNeasy
Mini Kit; Qiagen) following manufacturer’s protocol. Concen-
tration of RNA was measured using a spectrophotometer
(Thermo Fisher Scientific). Total RNA was reversed transcribed
using a reverse transcription kit (QuantiTect; Qiagen), and
qPCR performed using the following Taqman probes: Human
VEGFA Hs00900055_m1, and three reference genes, Human
GAPDH Hs99999905_m1, Human B2M Hs00984230, and
Human HPRT1 Hs99999909_m1 (Thermo Fisher Scientific).
Enzyme-Linked Immunosorbent Assay
For enzyme-linked immunosorbent assays, infected cells were
changed to low-serum media (DMEM:F12 with 1% FBS to
preserve VEGF stability) and conditioned media collected over
3 hours. Protein secretion of VEGF was measured using a
human VEGF ELISA kit (Quantikine; R&D systems, Minneap-
olis, MN, USA) following the manufacturer’s protocol, normal-
ized to total cell number per sample, and quantified using a
microplate reader (Versamax; Molecular Devices, Sunnyvale,
CA, USA).
Endothelial Cell Tube Formation
Human umbilical vascular endothelial cells (HUVECs) were
cultured in Medium 200PRF (Thermo Fisher Scientific)
supplemented with low serum growth supplement (Thermo
Fisher Scientific), in a humified incubator with 5% CO2 at 378C.
We coated 24-well plates with 10 mg/mL Matrigel (Corning,
Corning, NY, USA) and incubated at 378C for 30 minutes. We
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resuspended 25,000 HUVECs in unsupplemented media
(Thermo Fisher Scientific) with conditioned ARPE-19 media
in 200 lL total volume. The cells were incubated at 378C for 4
to 8 hours, then imaged using an inverted microscope (Eclipse
TE 200; Nikon Corp., Tokyo, Japan) at34 magnification. Tube
formation was quantified from five random fields for each
experiment using the Angiogenesis Analyzer for ImageJ tool,
and reported as total length (mm) per unit area (mm2).
Statistical Analysis
All results are presented as means 6 standard deviation. We
used 1-way ANOVA with Dunnett’s posttests to compare mRNA
levels, protein levels, and endothelial tube formation. Statistical
analyses were conducted using statistical software (SPSS
version 22.0; IBM Corp., Armonk, NY, USA).
RESULTS
gRNA Design for VEGF-A Disruption
Vascular endothelial growth factor A is a diffusible mitogen that
is secreted by RPE and other cells in the eye in response to
hypoxic and inflammatory stimuli. Alternatively spliced tran-
script variants give rise to at least seven homodimeric isoforms,
of which VEGF206, VEGF189, VEGF165, and VEGF121 represent
the major isoforms and are differentially expressed in ocular
neovascular conditions.21 Exons 1 through 5 and 8 are
conserved in all isoforms except VEGF148, and encode the
receptor-binding domain.22 To enable genomic disruption of all
VEGF isoforms, we designed CRISPR gRNAs to target locations
in exon 1 of the human VEGF-A gene (Supplemental Figs. S1A,
S1B), in which a frameshift mutation is most likely to result in
truncated, nonfunctional gene products. Using computational
methods to predict on-target Cas9 endonuclease activity and
off-target Cas9 binding, we identified site 1 for the highest on-
target and average on/off-target scores. Site 2 was selected for
the second highest on-target score. Site 3 was chosen for the
highest off-target score (lowest probability for off-target
effects). Sites 4 and 5 were identified using commercial
CRISPR design services (GeneArt; Thermo Fisher Scientific).
These five gRNA target sequences were individually cloned
into lentiCRISPR v2 constructs upstream of the gRNA scaffold
sequence (Supplemental Fig. S1C), and used to produce
lentiviral vectors that target VEGF-A. Viral vectors expressing
Cas9 only without VEGF-targeted gRNA sequences were used
as controls.
Genomic Disruption of VEGF-A Gene by
Programmed Cas9
Human RPE cell line ARPE-19 is a spontaneously arising cell
line that exhibits phenotypic characteristics of RPE such as
pigmentation, barrier property, and polarity of secreted
signals.23 They also have a similar pattern of VEGF isoform
expression as human RPE in vivo, including VEGF165 as the
predominant form, VEGF121, and VEGF189.
24,25 To demonstrate
the possibility of genomic disruption of VEGF-A in human RPE
cells, we infected ARPE-19 cells with Cas9-expressing lentiviral
vectors to target VEGF-A, and showed frequencies of indel
formation between 33.5% 6 3.8% and 37.0% 6 4.0% using the
T7 endonuclease I (T7E1) mismatch detection assay (Fig. 1A).
Formation of indel did not change significantly with higher
viral concentrations (up to MOI of 10; Supplemental Fig. S2).
Sanger sequencing confirmed that indel formation occurred at
the predicted sites (Fig. 1B), although the chromatogram for
target 5 suggests lower indel formation than the frequency
indicated by the T7E1 assay. Deep sequencing also confirmed
indel formation at the predicted sites, including a variety of
frameshift and in-frame mutations (Fig. 1C, Supplemental Fig.
S3). Interestingly, the gRNA with the highest on-target score (V-
1) produced the highest frequency of indels, although on-target
scores for other gRNAs did not always correlate directly with
the indel frequency.
Reduction of VEGF-A Secretion by Programmed
Cas9
To determine if genomic disruption of the VEGF-A gene
resulted in changes in mRNA or protein levels, we performed
quantitative RT-PCR on total RNA, and ELISA analysis on
conditioned media from the infected cells. Since Cas9
endonuclease activity only alters the DNA gene sequence to
introduce indel mutations, we would not expect significant
alterations in VEGF-A mRNA levels unless a transcriptional stop
or unstable RNA transcript has been created. Consistent with
this prediction, quantitative RT-PCR showed no significant
reduction in mRNA expression of VEGF-A after infection with
any of the Cas9 constructs (P ¼ 0.583; Fig. 2A). However, we
did note significant variability in mRNA levels between
individual experiments, suggesting possible effects on mRNA
stability in some cell populations that may be stochastic in
nature.
Using ELISA to measure VEGF-A protein levels, we found
that gRNAs with the highest indel frequencies resulted in
significant reduction of secreted VEGF-A, ranging from 20.8%
6 19.4% to 41.2% 6 7.4% (P < 0.001; Fig. 2B). Target V-5,
which had a lower on-target score and lower indel frequency
suggested by Sanger sequencing chromatograms, showed no
significant reduction in VEGF-A. These results demonstrate that
Cas9-mediated VEGF-A gene disruption can reduce VEGF
secretion from human RPE cells, and that computational
estimates of Cas9 activity may predict efficacy of gene product
suppression.
Reduction of In Vitro Angiogenesis by
Programmed Cas9
In addition to reducing the amount of secreted VEGF-A, Cas9-
mediated indel mutations may also lead to functional disrup-
tion of the VEGF-A protein. For example, missense mutations
may allow translation of full-length VEGF protein, but can
cause protein misfolding and functional loss. To measure
angiogenesis in vitro, we employed a human endothelial tube
formation assay using conditioned culture media from the
ARPE-19 cells. Consistent with the ELISA results, we detected a
30.5% 6 18.8% to 39.4% 6 9.8% decrease in tube formation (P
¼ 0.02), with the most significant reduction using conditioned
media that had the greatest reduction of VEGF-A levels (Fig. 3).
Thus, genomic disruption of VEGF-A in human RPE cells using
CRISPR-Cas9 may reduce angiogenesis in an in vitro model.
Off-Target Effects of Programmed VEGF-A Gene
Disruption
Cas9-mediated gene disruption may be susceptible to off-target
mutations if the gRNA sequences share homology with other
loci in the genome. To investigate potential off-target effects of
Cas9-mediated VEGF-A disruption, we investigated putative
exonic off-target sites for each gRNA sequence, based on the
level of homology with the target gRNA (Fig. 4A). Using the
T7E1 mismatch assay, we did not detect any nonspecific
cleavage activity at the three most probable off-target exonic
loci for any of the gRNA target sequences (Fig. 4B). These
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results suggest that Cas9-mediated disruption of VEGF-A in RPE
cells is highly selective with minimal off-target effects.
DISCUSSION
Genome engineering using CRISPR-Cas9 technology has
dramatically improved the efficiency and ease of creating
targeted genetic modifications, revolutionizing many aspects of
biologic and medical research in recent years. In this study, we
successfully employed the CRISPR-Cas9 system to achieve
genomic disruption of the VEGF-A gene in human RPE cells,
with a corresponding reduction in secreted VEGF-A protein,
suppression of angiogenesis in vitro, and no detectable off-
target effects. These results demonstrate as proof of principle
the feasibility of using CRISPR-Cas9 gene editing as potential
antiangiogenesis therapy in ocular neovascular diseases.
Although gene therapy has been employed with some
success in inherited retinal diseases that result from a single
gene defect, the concept of employing gene therapy in
complex, multifactorial diseases like AMD or diabetic retinop-
athy has not been explored at length due to the complex
interactions of various genetic factors and molecular pathways
involved in the pathogenesis of these conditions. However,
CRISPR-Cas9 gene editing technology is particularly well-suited
to address these conditions because multiplexed targeting of
different genes can be achieved by expressing a battery of
gRNAs with the Cas9 endonuclease in a single viral construct.
In addition to reducing VEGF, for example, other angiogenic,
exudative, and inflammatory pathways can be simultaneously
FIGURE 1. Cas9-mediated indel formation and DNA sequencing. (A) T7E1 mismatch detection assays demonstrating frequency of indel formation
(%indel) for each gRNA targeting VEGF-A, expressed in mean 6 standard deviation. Lentiviral vectors expressing SpCas9 without VEGF-targeted
gRNAs were used as controls. Representative results are shown from four total independent experiments. (B) Sanger sequencing chromatograms
showing indel formation at the predicted cut site for each target site. (C) Representative deep sequencing results for V-1 confirming indel formation
at the predicted cut site (red arrowhead), including insertions (bases in red) and deletions (dashes).
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targeted in the context of different classes of retinal disorders.
The system also affords tremendous specificity by selectively
disrupting individual genes, in contrast to siRNA-mediated
knockdown or dominant-negative protein expression that can
unpredictably affect multiple targets at once. Importantly,
manipulations at the genomic level lead to a permanent
disruption of the target gene or genes, even if long-term viral
expression of the Cas9 protein cannot be maintained. Hence,
CRISPR-Cas9 gene editing has significant advantages as a
strategy for human gene therapy.
In our studies, genomic disruption of VEGF-A with Cas9
using a single lentiviral system resulted in up to 41.2%
reduction in VEGF secretion from RPE cells. The incomplete
suppression may be due in part to incomplete Cas9 activity,
since our results demonstrated only up to 37.0% indel
formation, indicating that a portion of the cells did not
undergo Cas9-mediated cleavage of the target site. Our data
contrast with studies showing greater than 90% indel
frequency after lentiviral transduction of gRNAs targeting
enhanced green fluorescent protein (EGFP) in human embry-
onic kidney (HEK) 293T cells,26 but are comparable to the
38.6% indel formation in VEGF-A after plasmid transfection of
Cas9 with gRNAs in HEK293 cells.27 Hence, Cas9 activity is not
only determined by the specific target site, but also by the
particular cell type, gene of interest, and mode of Cas9/gRNA
delivery. Since RPE cells are not the only source of VEGF,28 and
other proangiogenic factors are involved in neovascular eye
conditions, further studies to target additional angiogenic
factors in other cell types may demonstrate more optimal Cas9
cleavage activity and greater suppression of angiogenesis.
Another reason for the incomplete reduction in VEGF
secretion is the fact that not all indels result in biallelic null
mutations. Rather than clonally expanding a single null mutant,
as common in loss-of-function studies, our goal was to assess
the direct application of this lentiviral CRISPR system to a
population of RPE cells for potential translation to human
therapy. We thus expect a mixture of biallellic null mutant,
haploinsufficient, and wild-type cells, even within the popu-
lation of cells that underwent Cas9 cleavage. Interestingly,
despite the prediction that only approximately two-thirds of
indels should lead to frameshift or nonsense mutations, and
even fewer having these mutations in both alleles, we were
surprised to detect similar decreases in both VEGF-A secretion
and tube formation, compared with the estimated indel
frequencies from the T7E1 assays. Based on the Sanger
sequencing chromatograms, we suspect that mismatch detec-
tion with the T7E1 assay may reflect only a minimum estimate
of actual indel frequencies.
Even if complete VEGF suppression cannot be achieved,
partial reduction of VEGF may be sufficient to suppress
neovascularization or exudation in vivo, or even just reduce
FIGURE 2. VEGF-A mRNA and protein levels after Cas9-mediated gene
disruption. (A) Levels of VEGF-A mRNA measured from quantitative RT-
PCR, showing no significant change in mRNA expression, following
expression of Cas9 with gRNAs targeting VEGF-A, compared with Cas9-
only controls. Results represent averaged values from three indepen-
dent experiments, with three replicate samples each. (B) Protein levels
of VEGF-A of conditioned media measured by ELISA, normalized to cell
number, showing significant reduction of secreted VEGF-A after Cas9-
mediated disruption of VEGF-A gene. Results represent averaged values
from seven independent experiments, with two replicate samples
each. Data are presented as mean 6 SEM. * P < 0.05, **P < 0.01, *** P <
0.001. Statistical values based on Dunnett’s posttests.
FIGURE 3. In vitro angiogenesis after Cas9-mediated VEGF-A disrup-
tion. (A–F) Representative phase contrast images of human endothelial
cell tube formation after exposure to conditioned medium from ARPE-
19 cells expressing Cas9 and guide RNAs targeting VEGF-A. Overlay
was generated by the angiogenesis analyzer tool on ImageJ. Scale bar:
200 lm. (G) Quantification of HUVEC tube formation from experi-
ments shown in (A–F) showing significant reduction in in vitro
angiogenesis activity. Results represent averaged values from six
independent experiments, with five random fields analyzed from each
experiment. Data are presented as mean 6 SEM. *P < 0.05, ** P < 0.01,
*** P < 0.001. Statistical values based on Dunnett’s posttests.
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the burden of frequent intravitreal injections of anti-VEGF
agents. In fact, total VEGF suppression may not be optimal, as
basal VEGF secretion is necessary for maintenance of the
choriocapillaris,29 and long-term VEGF suppression may be
associated with progression of geographic atrophy in patients
with AMD.30,31
The prospect of off-target mutations is of particular concern
to researchers interested in using CRISPR-Cas9 technology in
human therapeutic applications. The frequency of off-target
mutagenesis is somewhat controversial, with some reports
showing that Cas9 can efficiently discriminate on-target from
off-target sites that differ by two bases,32,33 and others noting
off-target mutations even at sites that differ by 5 nucleotides
from on-target sites.16,27,34 We did not detect any indel
formation at the three most probable off-target sites for each
VEGF gRNA used in this study, even though these off-target
sites differed by three or more base pairs and occur mainly in
the 50 upstream region of the protospacer, where Cas9
endonucleases are more likely to tolerate mismatches. Never-
theless, we cannot exclude the possibility of off-target
mutations at very low frequencies that are below the detection
limit of the T7EI assay or at other putative sites not examined
in our studies, which could be revealed by deep sequencing of
off-target sites or whole genome sequencing, respectively.
Strategies to improve the specificity of the CRISPR-Cas9 system
may include using a shorter 18 to 19 nt protospacer35 or paired
Cas9 nickases that generate two single-strand breaks on
opposite DNA strands,33,36 although the efficiency of Cas9
cleavage may be compromised. The use of an inducible37–39 or
cell-specific promoter to drive Cas9 expression may also
further improve the temporal and spatial control of endonu-
clease activity, which will minimize the accumulation of
random off-target mutations that may occur with long-term
overexpression. Novel Cas9 variants with improved specificity
are already in development,40 and may further mitigate
concerns of off-target mutagenesis.
Future studies will be necessary to assess the potential use
of CRISPR-Cas9 gene editing to target VEGF as an ocular
antiangiogenesis therapy. Use of primary human RPE cells,
such as human fetal RPE, or demonstration of gene editing in
vivo in a small animal model would further support the
translational potential of this strategy to human therapy. We
employed a lentiviral vector due to its efficiency in transducing
RPE cells and the availability of well-characterized tools for
predicting gRNA sequences for SpCas9. However, lentiviruses
randomly integrate into the host genome, potentially triggering
additional off-target effects such as activation of oncogenes or
inactivation of tumor suppressor genes, which may have
harmful consequences. Adeno-associated viruses have no
association with human disease and are more amenable to
FIGURE 4. Off-target activity of Cas9-mediated VEGF-A gene disruption. (A) Top three putative off-target sites for each target CRISPR sequence for
human VEGF-A, with respective on-target scores to predict off-target Cas9 activity at these locations. Only off-target sites located within gene exons
were chosen. Base mismatches are shown in red. (B) T7E1 mismatch detection assays of putative off-target sites, showing no detectable indel
formation at these locations.
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gene therapy, but have a limited packaging capacity. AAV-
mediated expression of the Staphylococcus aureus Cas9
(SaCas9) endonuclease, which is 1 kb shorter than SpCas9,
may provide a more feasible avenue for translational therapeu-
tic applications.
In conclusion, we successfully employed a CRISPR-Cas9
system to disrupt VEGF secretion from human RPE cells and
suppress angiogenesis in vitro, demonstrating as proof of
concept the possibility of employing gene editing strategies for
ocular antiangiogenesis therapy.
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